ViaCord and Cord Blood Registry are two of the nation's largest companies offering umbilical cord blood and tissue banking. ViaCord additionally tests maternal blood for infectious diseases and extracts cord tissue stem cells prior to storage to best prepare them for potential use. CBR, however, uses its own collection device designed specifically for higher collection volumes of cord blood stem cells.
In addition to collecting and storing cord blood and tissue, both ViaCord and CBR are involved in cutting-edge research to find new stem cell therapies for a variety of serious conditions such as cancer, juvenile diabetes, autism, cerebral palsy, traumatic brain injury and heart disease.
In 2013, ViaCord and CBR joined together to praise the Family Cord Blood Banking Act. The bipartisan legislation ensures that umbilical cord blood banking services are recognized as a qualified medical expense, allowing expectant parents to use tax-free dollars to pay for cord blood banking services.
CBR, founded in 1992, is the world's largest newborn stem cell company. The company stores more than 500,000 cord blood and cord tissue units, as of 2014. ViaCord is a division of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment.